Neumora Therapeutics, Inc. (NMRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami Fadia from Needham maintained a Buy rating on the stock and has a $5.00 price target.
Ami Fadia’s rating is based on a combination of factors that suggest potential upside for Neumora Therapeutics, Inc. despite some setbacks. The company has faced delays in its KOASTAL-2 and KOASTAL-3 studies, now expected to report results in 2026. However, management remains confident in the studies related to major depressive disorder (MDD), attributing previous negative results to anomalies and implementing improvements in study design and execution.
Ami Fadia also notes that while the discontinuation of the Phase 2 trial for navacaprant in bipolar disorder allows Neumora to better allocate resources, the company’s strategic adjustments and focus on the MDD studies could lead to significant gains if the upcoming results are favorable. Although immediate momentum in the stock is not anticipated, the potential for substantial positive outcomes from these studies supports the Buy rating.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com